Hannah Choe is a Hematology physician. OpenAlex indexes 243 publications with 2,407 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Sponsor: Hannah Choe, MD
- High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IncyteProgram year202535 paymentsResearch$110,917openpaymentsdata.cms.gov ↗
- SanofiProgram year20257 paymentsResearch$62,461openpaymentsdata.cms.gov ↗
- GSKProgram year20251 paymentResearch$58,656openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2025$415,000R01CA252469 - Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2024$394,251R01CA252469 - Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2023$406,701R01CA252469
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Journal of Hematology & Oncology
2025 - Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Jaroslaw Maciejewski, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”